Fulgent Genetics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, reporting a 3.0% beneficial ownership in Fulgent Genetics, Inc. as of December 31, 2025.
NASDAQ
Millennium Management LLC and affiliated entities, including Israel A. Englander, have disclosed a passive beneficial ownership of 5.6% in Fulgent Genetics, Inc. common stock.
NASDAQ
Millennium Management LLC and its affiliates have filed an Amendment No. 2 to their Schedule 13G, disclosing a 4.7% beneficial ownership stake in Fulgent Genetics, Inc. as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: Barclays PLC Discloses 7.57% Beneficial Stake in Fulgent Genetics Inc. via Amended Schedule 13G
Barclays PLC has filed an Amendment No. 2 to Schedule 13G, reporting a 7.57% beneficial ownership stake in Fulgent Genetics Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Millennium Management Amends Stake in Fulgent Genetics, Disclosing 6.5% Beneficial Ownership
Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has filed an amended Schedule 13G, disclosing a 6.5% beneficial ownership stake in Fulgent Genetics, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 5.9% Passive Stake in Fulgent Genetics
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.9% beneficial ownership in Fulgent Genetics, Inc. as a passive institutional investor.
NASDAQ
Barclays PLC has filed an amended Schedule 13G, revealing a passive beneficial ownership of 5.42% in Fulgent Genetics Inc. as of December 31, 2024.
NASDAQ
Ramya Rao, representing Barclays Bank PLC and its affiliates, has disclosed a 5.42% passive beneficial ownership stake in Fulgent Genetics Inc. common stock as of December 31, 2024.
NASDAQ
Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a passive beneficial ownership of 5.0% in Fulgent Genetics, Inc. common stock.